Generated by AI
Pulmatrix Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases and migraine. The company’s work centers on its proprietary iSPERSE engineered dry powder delivery platform, which is designed to deliver small and large molecule drugs directly to the lungs for local or systemic use. Pulmatrix’s current product candidates address serious conditions with unmet medical needs, including chronic obstructive pulmonary disease, allergic bronchopulmonary aspergillosis, and acute migraine. Its research and development activity is concentrated on creating inhaled formulations that may improve drug delivery efficiency and patient tolerability. Based in Framingham, Massachusetts, Pulmatrix operates within the biotechnology and pharmaceutical sectors, where it contributes to the development of specialized pulmonary-delivered therapeutics.
Website945 Concord Street
Framingham, MA, 01701
United States
Summary of Oct 27's posts. Generated by AI.
Summary of Mar 26's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about PULM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.